[go: up one dir, main page]

SMT201400117B - Glyx-13 per l'uso in un metodo di trattamento della depressione refrattaria - Google Patents

Glyx-13 per l'uso in un metodo di trattamento della depressione refrattaria

Info

Publication number
SMT201400117B
SMT201400117B SM201400117T SM201400117T SMT201400117B SM T201400117 B SMT201400117 B SM T201400117B SM 201400117 T SM201400117 T SM 201400117T SM 201400117 T SM201400117 T SM 201400117T SM T201400117 B SMT201400117 B SM T201400117B
Authority
SM
San Marino
Prior art keywords
glyx
treatment method
refractory depression
depression treatment
refractory
Prior art date
Application number
SM201400117T
Other languages
English (en)
Inventor
Joseph Moskal
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of SMT201400117B publication Critical patent/SMT201400117B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Ceramic Products (AREA)
  • Peptides Or Proteins (AREA)
SM201400117T 2009-10-05 2014-08-19 Glyx-13 per l'uso in un metodo di trattamento della depressione refrattaria SMT201400117B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24865009P 2009-10-05 2009-10-05
PCT/US2010/051415 WO2011044089A2 (en) 2009-10-05 2010-10-05 Methods of treating depression and other related diseases

Publications (1)

Publication Number Publication Date
SMT201400117B true SMT201400117B (it) 2014-11-10

Family

ID=43857351

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201400117T SMT201400117B (it) 2009-10-05 2014-08-19 Glyx-13 per l'uso in un metodo di trattamento della depressione refrattaria

Country Status (12)

Country Link
EP (4) EP2485751B1 (it)
CY (1) CY1118530T1 (it)
DK (2) DK2985032T3 (it)
ES (2) ES2493316T3 (it)
HR (1) HRP20140784T1 (it)
HU (1) HUE043807T2 (it)
PL (2) PL2985032T3 (it)
PT (2) PT2985032T (it)
RS (1) RS53513B1 (it)
SI (1) SI2485751T1 (it)
SM (1) SMT201400117B (it)
WO (1) WO2011044089A2 (it)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0918868B8 (pt) 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도
CN102933226A (zh) 2010-02-11 2013-02-13 西北大学 二级结构稳定化的nmda受体调节剂及其用途
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
SG10202010665YA (en) * 2011-04-27 2020-11-27 Univ Northwestern Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
US20150253305A1 (en) * 2012-10-12 2015-09-10 Northwestern University Methods of identifying compounds for treating depression and other related diseases
TR201908596T4 (tr) 2013-01-29 2019-07-22 Aptinyx Inc Spiro-laktam NMDA reseptörü modülatörleri ve bunların kullanımları.
KR20150110787A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
SG11201505862TA (en) 2013-01-29 2015-08-28 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
KR102410989B1 (ko) 2013-01-29 2022-06-17 앱티닉스 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
KR20150110586A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
MX2016007716A (es) * 2013-12-13 2017-03-31 Univ Northwestern Metodos para el tratamiento de trastornos cerebrales o la identificacion de biomarcadores relacionados con estos.
CN105327349A (zh) * 2014-06-18 2016-02-17 上海翰森生物医药科技有限公司 Nmda受体拮抗剂的医药用途及其药物组合物
CN106661085A (zh) * 2014-06-23 2017-05-10 西北大学 治疗或改善偏头痛的方法
WO2016025721A1 (en) * 2014-08-14 2016-02-18 Naurex, Inc. Methods of treating depression using nmda modulators
KR20180102052A (ko) * 2015-10-16 2018-09-14 노오쓰웨스턴 유니버시티 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용
US10591461B2 (en) 2016-04-28 2020-03-17 The Trustees Of The University Of Pennsylvania Method of drug design and optimisation utilizing stereochemical mimicry
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
KR102128675B1 (ko) 2016-05-19 2020-06-30 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
AU2017306136B2 (en) 2016-08-01 2021-10-21 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
AU2017306152A1 (en) 2016-08-01 2019-01-31 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
JP2019527235A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタム及びビス−スピロ−ラクタムnmda受容体修飾因子及びその使用
PE20190504A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
MX2020008107A (es) 2018-01-31 2020-09-25 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos.
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) * 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
AU2002248553A1 (en) * 2001-03-07 2002-09-24 Cognetix, Inc Linear y-carboxyglutamate rich conotoxins
AU2002255705A1 (en) * 2001-03-12 2002-09-24 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
CA2534909A1 (en) * 2003-08-08 2005-02-17 The Burnham Institute P16 mediated regulation of nmda receptors
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders

Also Published As

Publication number Publication date
ES2721448T3 (es) 2019-07-31
RS53513B1 (sr) 2015-02-27
EP2485751A2 (en) 2012-08-15
PT2485751E (pt) 2014-09-01
HUE043807T2 (hu) 2019-09-30
HRP20140784T1 (hr) 2014-10-10
ES2493316T3 (es) 2014-09-11
WO2011044089A3 (en) 2012-02-16
PT2985032T (pt) 2019-04-24
DK2985032T3 (en) 2019-04-15
PL2985032T3 (pl) 2019-07-31
EP3488856A1 (en) 2019-05-29
DK2485751T3 (da) 2014-08-18
WO2011044089A2 (en) 2011-04-14
CY1118530T1 (el) 2017-07-12
EP2985032B1 (en) 2019-01-02
EP2813236A1 (en) 2014-12-17
EP2985032A1 (en) 2016-02-17
EP2485751B1 (en) 2014-05-21
EP2485751A4 (en) 2013-03-13
PL2485751T3 (pl) 2014-10-31
SI2485751T1 (sl) 2014-10-30

Similar Documents

Publication Publication Date Title
SMT201400117B (it) Glyx-13 per l'uso in un metodo di trattamento della depressione refrattaria
IL193566A0 (en) Hpv-18-based papillomavirus vaccine
PL3258012T3 (pl) Sztuczny kamień
GB0607088D0 (en) Vaccine
BR112012004593A2 (pt) "método"
IL193661A0 (en) Papillomavirus vaccine
IL208338A0 (en) Patterned artificial marble slab
GB0616306D0 (en) Vaccines
PL2013546T3 (pl) Urządzenie podnośnikowe
ZA200901592B (en) Vaccine
GB0614460D0 (en) Vaccines
GB0625593D0 (en) Vaccine
GB0614962D0 (en) Complex for use in vaccines
ZA200808893B (en) HPV-16-Based Papillomavirus vaccine
GB0619820D0 (en) Vaccine
GB0608962D0 (en) Vaccine
GB0620816D0 (en) vaccine
GB0620337D0 (en) Vaccine
GB0620336D0 (en) Vaccine
GB0619826D0 (en) Vaccine
GB0620815D0 (en) Vaccine
GB0614476D0 (en) Vaccine
GB0619824D0 (en) Vaccine
GB0619822D0 (en) Vaccine
GB0619821D0 (en) Vaccine